

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Date: 13th May 2026

To
The Manager
Listing Compliance Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051, India

Symbol: SAKAR

Sub: Press Release - Consolidated and Standalone Audited Financial Results for the quarter and year ended March 31, 2026.

In continuation of outcome of Board meeting held on Tuesday, 12th May 2026 on the Consolidated and Standalone Audited Financial Results for the quarter and year ended March 31, 2026 we attach a copy of Press Release being issued by the Company.

This is for information and records.

Thanking You,

Yours faithfully,
FOR, SAKAR HEALTHCARE LIMITED

BHARAT SONI
COMPANY SECRETARY AND
COMPLIANCE OFFICER

Encl: As above

Q4FY26 – Sakar Healthcare Records 42% YoY Revenue Growth EBITDA Rises 67%

Ahmedabad, 12th May 2026 : Sakar Healthcare Ltd [NSE: SAKAR, with a research-driven API-integrated EU GMP approved oncology orals and injection manufacturing unit, has announced its audited financial results for the financial year ended 31st March 2026.

Q4 & FY26 Consolidated Financial Performance

Particulars (INR Lakhs)	Q4FY26	Q4FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenue from Operations	7,109.70	5,024.18	42%	25,173.60	17,758.47	42%
Gross Profit	4,271.61	3,557.06	20%	12,845.93	9,532.20	35%
<i>Gross Profit Margin (%)</i>	60%	71%		51%	54%	
EBITDA	2,623.57	1,572.47	67%	6,888.82	4,968.32	39%
<i>EBITDA Margin (%)</i>	37%	31%		27%	28%	
Profit After Tax	1,102.43	576.11	91%	3,048.46	1,750.20	74%
<i>PAT Margin</i>	16%	11%		12%	10%	

Business Highlights for Q4 & FY26

- Completed over 60 Business Contracts with oncology products & over 35 discussions are ongoing
- Of 250 dossiers shared globally, 125 have been submitted and 12 have received Marketing Authorizations from Regulatory Authorities
- 21 of 32 developed oncology products dossiers shared; of which 11 dossiers have received approval (Abiraterone-1, Imatinib-1, Tamoxifen-1, Capecitabine-1, Gemcitabine-2, Carboplatin-3, Irinotecan-1, Docetaxel-2)
- Technology Transfer projects with oncology products are ongoing for Accord-Intas, Torrent-UK & Germany, Emcure, Glenmark, Zydus of which 4 have received site variation approvals (2 each in the UK and in EU)



Financial Highlights for Q4 & FY26

- Revenue for Q4FY26 stood at 7,110 lakhs, reflecting 42% YoY growth. Performance was supported by new market authorizations with oncology products and strong demand across countries, alongside continued execution across key initiatives
- EBITDA increased to ₹2,624 lakhs, up 67% YoY; EBITDA margins stood at 37%
- Company delivered a strong improvement in profitability, with PAT margin at 16% expanding sharply YoY, reflecting operating leverage, improved efficiencies, and disciplined cost management


Commenting on the Results, Mr. Sanjay Shah, Managing Director said,

Q4 marked another meaningful step forward for Sakar Healthcare, with strong year-on-year growth and improved profitability reflecting steady execution across the business. The quarter also underlined the increasing importance of oncology in our overall growth strategy, as the division continues to scale up and gradually shape the company's future growth profile. This progress is being supported by a widening product base, improving market reach, and a growing export opportunity across key markets.



As approvals continue to convert into launches and commercial supplies, we believe the business is entering a stronger and more sustainable growth phase. The oncology platform, in particular, remains well placed to benefit from rising volumes, better capacity utilisation, and operating leverage as scale improves. Looking ahead, FY27 is expected to be an important year for the company, with export momentum likely to strengthen further and oncology volumes continuing to ramp up, supporting the next phase of growth for Sakar Healthcare.

About Sakar HealthCare Limited:

Established in 2004 and headquartered in Ahmedabad, Gujarat, Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products. Sakar's oncology division at Bavla represents a research-driven, API-integrated facility focused on developing and commercializing complex cytotoxic formulations and APIs, underscoring its commitment to innovation and quality. With an extensive global footprint across more than 60 countries, Sakar serves as a trusted partner to multinational pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations. Driven by its vision to deliver world-class healthcare solutions that make lives healthier and more meaningful, Sakar continues to expand its presence across regulated markets through strong R&D capabilities, regulatory excellence, and sustainable manufacturing practices rooted in green chemistry principles.



Contact Details

Sakar HealthCare Limited	Investor Relations: MUFG Intime India Private Limited
 Sakar Healthcare Ltd.	 MUFG
CIN - L24231GJ2004PLC043861	Mr. Nikunj Seth Ms. Sejal Bhattar +91 9773397958 +91 7666736666
Mr. Dharmesh Thaker CFO info@sakarhealthcare.com	nikunj.seth@in.mpms.mufg.com sejal.bhattar@in.mpms.mufg.com

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.